GlobalData on MSN13h
Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejectionEurope’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.
GlobalData on MSN12d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCAThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for ...
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...
The European Commission (EC) will now review the CHMP recommendation, and a decision on the label extension application of IXCHIQ ® in the European Union (EU), Norway, Liechtenstein and Iceland is ...
Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, ...
About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback